상세 보기
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
- Keam, Bhumsuk;
- Ock, Chan-Young;
- Kim, Tae Min;
- Oh, Do-Youn;
- Kang, Won Ki;
- ... Park, Yeon Hee;
- ... Lee, Jeeyun;
- ... Park, Young Suk;
- 외 7명
WEB OF SCIENCE
3SCOPUS
3초록
Introduction IMC-001 is a fully human IgG1 monoclonal antibody that binds to human PD-L1 (programmed death-ligand 1). This study evaluated the safety, pharmacokinetics, and pharmacodynamics of IMC-001 in patients with advanced solid tumors. Materials and Methods This open-labeled phase I study used a standard 3 + 3 dose-escalation design, with doses ranging from 2 to 20 mg/kg. IMC-001 was administered intravenously every 2 weeks until disease progression or unacceptable toxicity. The dose-limiting toxicity window was defined as 21 days from the first dose. Results Fifteen subjects were included in 5 dose-escalation cohorts. No dose-limiting toxicity was observed, and the maximum tolerated dose was not reached. The most common adverse events (AEs) were general weakness, decreased appetite, fever, and cough. No grade 4 or 5 treatment emergent AEs were reported during the study. One subject in the 2 mg/kg cohort showed grade 2 immune-induced thyroiditis and diabetes mellitus suspected to be related to IMC-001. Over the dose range of 2-20 mg/kg IMC-001, the AUC(0-14d), AUC(0-infinity), and C-max generally increased in a dose-proportional manner for each step of dose escalation. Of the 15 enrolled patients, 1 subject with rectal cancer showed a partial response, and the disease control rate was 33.3%. Conclusions IMC-001 demonstrated a favorable safety profile up to 20 mg/kg administered intravenously every 2 weeks and showed preliminary efficacy in patients with advanced solid tumors. Based on pharmacokinetic and pharmacodynamic data, 20 mg/kg was selected as the recommended phase II dose. Clinical trial identification NCT03644056 (date of registration: August 23, 2018).
키워드
- 제목
- A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
- 저자
- Keam, Bhumsuk; Ock, Chan-Young; Kim, Tae Min; Oh, Do-Youn; Kang, Won Ki; Park, Yeon Hee; Lee, Jeeyun; Lee, Ji Hye; Ahn, Yoen Hee; Kim, Hyeon Ju; Chang, Sook Kyung; Park, Jihyun; Choi, Ji Yea; Song, Yun Jeong; Park, Young Suk
- 발행일
- 2021-12
- 유형
- Article
- 권
- 39
- 호
- 6
- 페이지
- 1624 ~ 1632
- 언어
- ENG
- 출판사
- Kluwer Academic Publishers
- 발행국가
- 네덜란드
- 분량
- 9 페이지
- ISSN
- E 1573-0646
P 0167-6997